<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424161</url>
  </required_header>
  <id_info>
    <org_study_id>C-18-SRF01</org_study_id>
    <nct_id>NCT03424161</nct_id>
  </id_info>
  <brief_title>Multi-Center, Clinical Evaluation of the Cutera Secret RF Device</brief_title>
  <official_title>Multi-Center, Clinical Evaluation of the Cutera Secret RF Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy and safety of the Cutera Secret RF
      device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, study in approximately 40 subjects, ages 18 to 65. Subjects may
      receive up to four treatments and will be followed at 4 and 12 weeks post the final
      treatment. A small subgroup of subjects may elect to have a biopsy of the treatment area
      prior to and after treatment. (Immediate, 72 Hours post initial treatment and 3 months post
      last treatment).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Skin Quality Assessment</measure>
    <time_frame>Changes from Baseline at 4 weeks follow-up, and at 12 weeks follow-up</time_frame>
    <description>Efficacy of treatment(s) with Cutera Secret RF measuring the changes in skin quality from Baseline to the 4 week follow-up visit, and from Baseline to the 12 week follow-up visit, as assessed by the study investigator using Skin Quality Rating Scale (1-10) for Radiance(1=No Radiance/worst to 10=maximum radiance/best), Smoothness(1=Very Rough/worst to 10=Very Smooth/best), Pigmentation(Very Irregular pigmentation/worst to 10=Very Uniform pigmentation/best), Erythema(1=Intense redness/worst to 10=No redness/best), and Pore size(1=Very Large pores/worst to 10=Minimal pores/best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Acne Scar Assessment, if present</measure>
    <time_frame>Changes from Baseline at 4 weeks follow-up, and at 12 weeks follow-up</time_frame>
    <description>Efficacy of treatment(s) with Cutera Secret RF measuring the changes in acne scarring from Baseline to the 4 week follow-up visit, and from Baseline to the 12 week follow-up visit, as assessed by the study investigator using ASAS: Acne scar Severity Assessment Scale if scars are present (+1=clear/best, +2=very mild, +3=mild, +4=moderate, or +5=severe/worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement in Wrinkle Assessment</measure>
    <time_frame>Changes from Baseline at 4 weeks follow-up, and at 12 weeks follow-up</time_frame>
    <description>Efficacy of treatment(s) with Cutera Secret RF measuring the changes in number and depth of wrinkles from Baseline to the 4 week follow-up visit, and from Baseline to the 12 week follow-up visit as assessed by the study investigator using FWCS: Fitzpatrick Wrinkle Classification System (1-3=fine wrinkles, 4-6=moderate depth of wrinkles &amp; moderate number of lines, 7-9=severe depth of wrinkles &amp; numerous lines)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Aesthetic Improvement</measure>
    <time_frame>at 4 weeks follow-up and 12 weeks follow-up</time_frame>
    <description>Efficacy of treatment(s) with Cutera Secret RF measuring the global skin improvement at the 4 week follow-up visit, and at the 12 week follow-up visit as assessed by the study investigator using GAIS: Global Aesthetic Improvement Scale (+4=Very Significant Improvement (â‰¥75%), +3=Significant Improvement (50-74%), +2=Moderate Improvement (25-49%), +1=Mild Improvement (5-24%), or 0=No Change (&lt;5%))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Safety</measure>
    <time_frame>through study completion, an average of 1+1/2 years</time_frame>
    <description>Safety of the Cutera Secret RF laser as measured by the frequency and severity (0=none, 1=mild, 2=moderate, or 3=severe) of device related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Skin Quality</condition>
  <arm_group>
    <arm_group_label>Secret RF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with Secret RF for skin quality</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Secret RF</intervention_name>
    <description>Subjects may receive up to 4 treatments</description>
    <arm_group_label>Secret RF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject must be able to read, understand and sign the Informed Consent Form.

          2. Female or Male, 18 to 65 years of age (inclusive).

          3. Willing to undergo treatments with Secret RF.

          4. Willing to have very limited sun exposure and use sunscreen on the treatment area
             every day for the duration of the study, including the follow-up period.

          5. Subject must adhere to the follow-up schedule and study instructions.

          6. Agree to not undergo any other cosmetic procedure(s) or treatment(s) on the treatment
             area during the study and has no intention of having such procedures performed during
             the course of the study.

          7. Willing to have digital photographs taken of the treatment area and agree to use of
             photographs for presentation, (educational and/or marketing), publications, and any
             additional marketing purposes.

          8. For female subjects: not pregnant or lactating and is either post-menopausal,
             surgically sterilized, or using a medically acceptable form of birth control prior to
             enrollment and during the entire course of the study.

        Exclusion Criteria:

          1. Participation in a clinical trial of another device or drug within 1 month of study
             participation, or during the study period.

          2. History of clotting disorders and/or current use of blood thinning medications.

          3. History of autoimmune disorders or diabetes.

          4. Cardiac pacemaker or active implantable metal device in the treatment area.

          5. Allergies to metals i.e. gold.

          6. Has a history of squamous cell carcinoma or melanoma in the treatment area.

          7. Significant uncontrolled concurrent illness that in the opinion of the Investigator
             would make the subject unsuitable for inclusion.

          8. History of any disease or condition that could impair wound healing.

          9. History of keloid formation or abnormal/delayed wound healing.

         10. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes
             zoster (shingles) in the treatment area, unless treatment is conducted following a
             prophylactic regimen.

         11. Use of topical agents one week prior to treatment that may cause facial sensitivity.

         12. Suffering from significant skin conditions in the treated areas or inflammatory skin
             conditions, including but not limited to, open lacerations or abrasions, hidradenitis,
             rash, infection , or dermatitis of the treatment area prior to treatment (duration of
             resolution as per the Investigator's discretion).

         13. As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study or a condition that would
             compromise the subject's ability to comply with the study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Ronan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cutera Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Bell</last_name>
    <phone>415-657-5722</phone>
    <email>mbell@cutera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Pocock</last_name>
    <phone>415-657-5702</phone>
    <email>gpocock@cutera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cutera Research Center</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mischell San Juan</last_name>
      <phone>415-657-5544</phone>
      <email>msanjuan@cutera.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Ronan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mishell San Juan, NP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

